Shilpa Medicare launches breakthrough therapy lenvatinib mesylate under brand Lenshil in India MD bureau3 Feb 2020 7:52 AM GMT Shilpa Medicare shall launch lenvatinib, at a breakthrough price which is over 50% lower than the existing brand available in India. Prior to the...
Shilpa Medicare gets 5 USFDA observations for Raichur facility Medical Dialogues Bureau31 July 2019 4:00 AM GMT"We have received Form 483 with five observations, with no repeat observations and any data integrity observations. The observations are mostly...